The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance and Faslodex.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

Pfizer is to make its breast cancer drug Ibrance (palbociclib) available for free to NHS patients while it waits for a final decision on the drug’s cost-effectiveness. The drug has been hailed ...

The cost-effectiveness agency has said that Ibrance (palbociclib) plus fulvestrant can be used routinely on the NHS as a second-line therapy for patients with advanced hormone receptor-positive ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival results show that the Itovebi-based regimen not only delayed disease ...

Opens in a new tab or window My main highlight from the meeting this year are the results from the PATINA trial assessing the addition of CDK4/6 inhibitors, or palbociclib, to maintenance ...

in combination with palbociclib (Ibrance ®) and fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine ...

Further results from the randomised, double-blind trial (NCT04191499) showed that Itovebi, otherwise known as inavolisib, when used in combination with Ibrance (palbociclib) and Faslodex ...